SG11202108645YA - Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses - Google Patents
Antibodies that bind tumor tissue, and their diagnostic and therapeutic usesInfo
- Publication number
- SG11202108645YA SG11202108645YA SG11202108645YA SG11202108645YA SG11202108645YA SG 11202108645Y A SG11202108645Y A SG 11202108645YA SG 11202108645Y A SG11202108645Y A SG 11202108645YA SG 11202108645Y A SG11202108645Y A SG 11202108645YA SG 11202108645Y A SG11202108645Y A SG 11202108645YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- diagnostic
- tumor tissue
- therapeutic uses
- bind tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806310P | 2019-02-15 | 2019-02-15 | |
| US201962806285P | 2019-02-15 | 2019-02-15 | |
| US201962843298P | 2019-05-03 | 2019-05-03 | |
| US201962843751P | 2019-05-06 | 2019-05-06 | |
| US201962852830P | 2019-05-24 | 2019-05-24 | |
| US201962927501P | 2019-10-29 | 2019-10-29 | |
| PCT/US2020/018350 WO2020168231A2 (en) | 2019-02-15 | 2020-02-14 | Antibodies that bind tumor tissue for diagnosis and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108645YA true SG11202108645YA (en) | 2021-09-29 |
Family
ID=69845562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108645YA SG11202108645YA (en) | 2019-02-15 | 2020-02-14 | Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11472885B2 (en) |
| EP (2) | EP3806895B1 (en) |
| JP (1) | JP7365421B2 (en) |
| KR (1) | KR102592844B1 (en) |
| CN (1) | CN114040774A (en) |
| AU (1) | AU2020223356B2 (en) |
| BR (1) | BR112021016121A2 (en) |
| CA (1) | CA3129637A1 (en) |
| DK (1) | DK3806895T3 (en) |
| ES (1) | ES2956413T3 (en) |
| FI (1) | FI3806895T3 (en) |
| IL (1) | IL285541A (en) |
| MX (1) | MX2021009727A (en) |
| NZ (1) | NZ782502A (en) |
| PL (1) | PL3806895T3 (en) |
| PT (1) | PT3806895T (en) |
| SG (1) | SG11202108645YA (en) |
| TW (1) | TW202045542A (en) |
| WO (1) | WO2020168231A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3194607A1 (en) * | 2020-10-05 | 2022-04-14 | Brian D. O'DONOVAN | Markers for the early detection of colon cell proliferative disorders |
| WO2022081843A1 (en) * | 2020-10-15 | 2022-04-21 | Atreca, Inc. | Antibody scaffold structure |
| CN113447648B (en) * | 2021-07-01 | 2022-04-19 | 浙江大学 | Kit for detecting anti-serine/arginine-rich splicing factor 9-IgG antibody |
| WO2023010057A1 (en) * | 2021-07-28 | 2023-02-02 | Atreca, Inc. | Atrc-101 target expression assay |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100566859B1 (en) | 1997-01-21 | 2006-04-03 | 제너럴 하스피톨 코포레이션 | Selection of proteins using rna-protein fusions |
| US6261804B1 (en) * | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| WO2005040810A1 (en) * | 2003-10-15 | 2005-05-06 | Roche Diagnostics Gmbh | Use of protein hnrnp-k as a marker for breast cancer |
| EP1766017B1 (en) * | 2004-06-10 | 2015-01-21 | Viventia Bio Inc. | Tumor specific antibody |
| CN104169419A (en) | 2011-12-23 | 2014-11-26 | 艾根股份有限公司 | Compositions and methods for the delivery of biologically active RNAs |
| US20150011405A1 (en) | 2013-07-03 | 2015-01-08 | Atreca, Inc. | Use of Nanoexpression to Interrogate Antigen Repertoires |
| WO2017010568A1 (en) | 2015-07-16 | 2017-01-19 | 国立大学法人京都大学 | Rna-protein complex and use thereof |
-
2020
- 2020-02-14 US US16/792,115 patent/US11472885B2/en active Active
- 2020-02-14 FI FIEP20712121.1T patent/FI3806895T3/en active
- 2020-02-14 EP EP20712121.1A patent/EP3806895B1/en active Active
- 2020-02-14 SG SG11202108645YA patent/SG11202108645YA/en unknown
- 2020-02-14 WO PCT/US2020/018350 patent/WO2020168231A2/en unknown
- 2020-02-14 NZ NZ782502A patent/NZ782502A/en active IP Right Revival
- 2020-02-14 EP EP23170070.9A patent/EP4253422A3/en active Pending
- 2020-02-14 MX MX2021009727A patent/MX2021009727A/en unknown
- 2020-02-14 JP JP2021547875A patent/JP7365421B2/en active Active
- 2020-02-14 CN CN202080029417.4A patent/CN114040774A/en active Pending
- 2020-02-14 CA CA3129637A patent/CA3129637A1/en active Pending
- 2020-02-14 AU AU2020223356A patent/AU2020223356B2/en active Active
- 2020-02-14 PL PL20712121.1T patent/PL3806895T3/en unknown
- 2020-02-14 BR BR112021016121A patent/BR112021016121A2/en unknown
- 2020-02-14 PT PT207121211T patent/PT3806895T/en unknown
- 2020-02-14 DK DK20712121.1T patent/DK3806895T3/en active
- 2020-02-14 KR KR1020217029134A patent/KR102592844B1/en active IP Right Grant
- 2020-02-14 ES ES20712121T patent/ES2956413T3/en active Active
- 2020-02-15 TW TW109104902A patent/TW202045542A/en unknown
-
2021
- 2021-08-11 IL IL285541A patent/IL285541A/en unknown
-
2022
- 2022-09-26 US US17/935,152 patent/US20230140035A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020223356A1 (en) | 2021-10-07 |
| BR112021016121A2 (en) | 2022-01-04 |
| FI3806895T3 (en) | 2023-09-13 |
| DK3806895T3 (en) | 2023-07-24 |
| AU2020223356B2 (en) | 2023-12-07 |
| EP3806895A2 (en) | 2021-04-21 |
| US20200325242A1 (en) | 2020-10-15 |
| WO2020168231A3 (en) | 2020-09-24 |
| TW202045542A (en) | 2020-12-16 |
| KR20210139258A (en) | 2021-11-22 |
| PL3806895T3 (en) | 2024-02-19 |
| ES2956413T3 (en) | 2023-12-20 |
| US11472885B2 (en) | 2022-10-18 |
| US20230140035A1 (en) | 2023-05-04 |
| NZ782502A (en) | 2023-10-27 |
| EP4253422A3 (en) | 2023-12-06 |
| WO2020168231A2 (en) | 2020-08-20 |
| JP2022520479A (en) | 2022-03-30 |
| IL285541A (en) | 2021-09-30 |
| KR102592844B1 (en) | 2023-10-20 |
| PT3806895T (en) | 2023-07-27 |
| JP7365421B2 (en) | 2023-10-19 |
| EP4253422A2 (en) | 2023-10-04 |
| CA3129637A1 (en) | 2020-08-20 |
| CN114040774A (en) | 2022-02-11 |
| EP3806895B1 (en) | 2023-06-21 |
| MX2021009727A (en) | 2021-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202108645YA (en) | Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses | |
| IL271888A (en) | Therapeutic and diagnostic methods for cancer | |
| EP4233909A3 (en) | Anti-cmet antibody drug conjugates and methods for their use | |
| IL280707A (en) | Diagnostic and therapeutic methods for the treatment of breast cancer | |
| IL268396A (en) | Diagnostic and therapeutic methods for cancer | |
| IL274246A (en) | Diagnostic and therapeutic methods for cancer | |
| WO2016055432A3 (en) | Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents | |
| CA3055791A1 (en) | Treatment methods | |
| CA3045495A1 (en) | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens | |
| IL273071A (en) | Diagnostic and therapeutic methods for cancer | |
| EA202092085A1 (en) | THERAPEUTIC ANTIBODIES AGAINST sPLA2-GIB AND THEIR APPLICATION | |
| IL281486A (en) | Therapeutic and diagnostic methods for bladder cancer | |
| ZA202108843B (en) | Novel psma specific binding proteins for cancer diagnosis and treatment | |
| IL281439A (en) | Combination therapy for treating blood cancer | |
| IL284097A (en) | Novel folr1 specific binding proteins for cancer diagnosis and treatment | |
| MX2020002750A (en) | Il-6r antibody and antigen binding fragment thereof and medical use. | |
| WO2016007919A3 (en) | Antibody fragments for detecting cancer and methods of use | |
| IL274177A (en) | Therapeutic substances, their preparation and diagnostic procedure | |
| EP3740755C0 (en) | Use of the tas1r3 protein as a marker for therapeutic, diagnostic, and/or prognostic purposes for tumors that express said protein | |
| GB201910130D0 (en) | Therapeutic and diagnostic target | |
| GB201900418D0 (en) | Therapeutic and diagnostic target | |
| GB201900401D0 (en) | Therapeutic and diagnostic target | |
| GB201900408D0 (en) | Therapeutic and diagnostic target | |
| GB201900411D0 (en) | Therapeutic and diagnostic target | |
| GB201900423D0 (en) | Therapeutic and diagnostic target |